Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C22H36N4O5 |
Molecular Weight | 436.545 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 2 / 2 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CN1C(=O)N(C[C@@H]([C@@H](CC2CCCC2)C(=O)N3CCCCC3)C(=O)NO)C(=O)C1(C)C
InChI
InChIKey=GFUITADOEPNRML-SJORKVTESA-N
InChI=1S/C22H36N4O5/c1-22(2)20(29)26(21(30)24(22)3)14-17(18(27)23-31)16(13-15-9-5-6-10-15)19(28)25-11-7-4-8-12-25/h15-17,31H,4-14H2,1-3H3,(H,23,27)/t16-,17+/m1/s1
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/11371662Curator's Comment: the description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/9179398 | https://www.ncbi.nlm.nih.gov/pubmed/24491581
Sources: https://www.ncbi.nlm.nih.gov/pubmed/11371662
Curator's Comment: the description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/9179398 | https://www.ncbi.nlm.nih.gov/pubmed/24491581
Cipemastat (Ro 32-3555, tentative trade name Trocade) is a dipeptide, potent, competitive inhibitor of matrix metalloproteinases (MMP) 1, 8 and 13, which was under development by Roche for the potential treatment of rheumatoid arthritis. Cipemastat is a selective inhibitor of metalloproteinases 1, 8 and 13 over the related human matrix metalloproteinases stromelysin 1, and gelatinases A and B. Cipemastat mediated MMP inhibition leads to block the final common event in the destructive cascade resulting in the breakdown of cartilage and bone. Trocade has also been shown to inhibit cartilage destruction in vivo and to prevent structural joint damage in animal models of rheumatoid and osteoarthritis. Cipemastat was in phase II clinical trials for the treatment of rheumatoid arthritis. However, Roche discontinued the development of cipemastat because of an unfavorable risk-benefit profile.
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL332 Sources: https://www.ncbi.nlm.nih.gov/pubmed/19422229 |
2.3 nM [IC50] | ||
Target ID: CHEMBL4588 Sources: https://www.ncbi.nlm.nih.gov/pubmed/10669559 |
4.0 nM [Ki] | ||
Target ID: CHEMBL280 Sources: https://www.ncbi.nlm.nih.gov/pubmed/19422229 |
4.7 nM [IC50] | ||
Target ID: CHEMBL321 Sources: https://www.ncbi.nlm.nih.gov/pubmed/19422229 |
2.4 nM [IC50] | ||
Target ID: CHEMBL4073 Sources: https://www.ncbi.nlm.nih.gov/pubmed/19422229 |
18.5 nM [IC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
3323 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/11371662 |
150 mg 1 times / day multiple, oral dose: 150 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
CIPEMASTAT plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FED |
|
3566 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/11371662 |
150 mg single, oral dose: 150 mg route of administration: Oral experiment type: SINGLE co-administered: |
CIPEMASTAT plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FED |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
19.71 mg × h/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/11371662 |
150 mg 1 times / day multiple, oral dose: 150 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
CIPEMASTAT plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FED |
|
20.66 mg × h/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/11371662 |
150 mg single, oral dose: 150 mg route of administration: Oral experiment type: SINGLE co-administered: |
CIPEMASTAT plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FED |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
23.9 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/11371662 |
150 mg 1 times / day multiple, oral dose: 150 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
CIPEMASTAT plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FED |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/11371662
25, 50, 100 or 150 mg once daily for 28 days.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/9179398
Bovine nasal cartilage explants (25 ± 30 mg) were cultured at 37C in Dulbecco's modified Eagle's medium (DMEM) containing penicillin (50 mkg/ml, streptomycin (50 mg/ml) and fungizone (250 mg/ml). Degradation of collagen was induced by the addition of114 ng/ml of rHu-IL-1alpha to the culture medium, the cultures were incubated for 15 days. During this period culture media containing rHu-IL-1alpha and Cipemastat were renewed every 7 days. When a considerable portion of each cartilage piece had degraded, the assay was stopped by removing the remaining cartilage explant and then analyzed for hydroxyproline, as a marker of cartilage collagen content. Glucose utilization was determined by measuring the glucose concentration in culture medium around the explants at the end of the experiment. The samples were analyzed by a COBAS Bio (Roche Diagnostics) with a GlucHK-unimate 5 test kit. Ro 32-3555 inhibited interleukin-1a (IL-1a)-induced cartilage collagen degradation in vitro in bovine nasal cartilage explants with IC50=60 nM.
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C1970
Created by
admin on Fri Dec 15 15:55:08 GMT 2023 , Edited by admin on Fri Dec 15 15:55:08 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
DTXSID10897569
Created by
admin on Fri Dec 15 15:55:08 GMT 2023 , Edited by admin on Fri Dec 15 15:55:08 GMT 2023
|
PRIMARY | |||
|
02HQ4TYQ60
Created by
admin on Fri Dec 15 15:55:08 GMT 2023 , Edited by admin on Fri Dec 15 15:55:08 GMT 2023
|
PRIMARY | |||
|
LL-08
Created by
admin on Fri Dec 15 15:55:08 GMT 2023 , Edited by admin on Fri Dec 15 15:55:08 GMT 2023
|
PRIMARY | |||
|
9824350
Created by
admin on Fri Dec 15 15:55:08 GMT 2023 , Edited by admin on Fri Dec 15 15:55:08 GMT 2023
|
PRIMARY | |||
|
SUB16410MIG
Created by
admin on Fri Dec 15 15:55:08 GMT 2023 , Edited by admin on Fri Dec 15 15:55:08 GMT 2023
|
PRIMARY | |||
|
C96297
Created by
admin on Fri Dec 15 15:55:08 GMT 2023 , Edited by admin on Fri Dec 15 15:55:08 GMT 2023
|
PRIMARY | |||
|
CIPEMASTAT
Created by
admin on Fri Dec 15 15:55:09 GMT 2023 , Edited by admin on Fri Dec 15 15:55:09 GMT 2023
|
PRIMARY | |||
|
CHEMBL115653
Created by
admin on Fri Dec 15 15:55:08 GMT 2023 , Edited by admin on Fri Dec 15 15:55:08 GMT 2023
|
PRIMARY | |||
|
190648-49-8
Created by
admin on Fri Dec 15 15:55:08 GMT 2023 , Edited by admin on Fri Dec 15 15:55:08 GMT 2023
|
PRIMARY | |||
|
7862
Created by
admin on Fri Dec 15 15:55:08 GMT 2023 , Edited by admin on Fri Dec 15 15:55:08 GMT 2023
|
PRIMARY | |||
|
100000078557
Created by
admin on Fri Dec 15 15:55:08 GMT 2023 , Edited by admin on Fri Dec 15 15:55:08 GMT 2023
|
PRIMARY |
ACTIVE MOIETY